Nikolaos Drakoulis

Prof. Dr. Nikolaos Drakoulis

1. Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15771 Zografou, Greece
+1
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2018 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
DBDaniel Boda
Daniel Boda
Anca Oana DoceaAnca Oana Docea
Anca Oana Docea
Daniela CalinaDaniela Calina
Daniela Calina
MIMihaela Adriana Ilie
Mihaela Adriana Ilie
Constantin CaruntuConstantin Caruntu
Constantin Caruntu
Aristidis TsatsakisAristidis Tsatsakis
Aristidis Tsatsakis
Human papilloma viruses (HPV) are a small group of non‑enveloped viruses belonging to the Papillomaviridae family with strong similarities to polyoma viruses. The viral particles consist of a genome in the form of a circular double‑stranded DNA, encompassing eight open reading frames, as well as a non‑enveloped icosahedral capsid. HPV infection is considered the most common sexually transmitted disease in both sexes and is strongly implicated in the pathogenesis of different types of cancer. ‘High‑risk’ mucosal HPV types, predominantly types 16, 18, 31, 33 and 35, are associated with most cervical, penile, vulvar, vaginal, anal, oropharyngeal cancers and pre‑cancers. Screening for HPV is necessary for the prognosis and for determining treatment strategies for cancer. Novel HPV markers, including proteomic and genomic markers, as well as anti‑papillomavirus vaccines are currently available. The aim of this comprehensive review was to thoroughly present the updated information on virus development, cancer occurrence, treatment and prevention strategies, in an attempt to shed further light into the field, including novel research avenues.

23 August 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Aristidis TsatsakisAristidis Tsatsakis
Aristidis Tsatsakis
Anca Oana DoceaAnca Oana Docea
Anca Oana Docea
Daniela CalinaDaniela Calina
Daniela Calina
Konstantinos TsarouhasKonstantinos Tsarouhas
Konstantinos Tsarouhas
LZLaura-Maria Zamfira
Laura-Maria Zamfira
Monica NeaguMonica Neagu
Monica Neagu
Drugs of abuse are associated with stroke, especially in young individuals. The major classes of drugs linked to stroke are cocaine, amphetamines, heroin, morphine, cannabis, and new synthetic cannabinoids, along with androgenic anabolic steroids (AASs). Both ischemic and hemorrhagic stroke have been reported due to drug abuse. Several common mechanisms have been identified, such as arrhythmias and cardioembolism, hypoxia, vascular toxicity, vascular spasm and effects on the thrombotic mechanism, as causes for ischemic stroke. For hemorrhagic stroke, acute hypertension, aneurysm formation/rupture and angiitis-like changes have been implicated. In AAS abuse, the effect of blood pressure is rather substance specific, whereas increased erythropoiesis usually leads to thromboembolism. Transient vasospasm, caused by synthetic cannabinoids, could lead to ischemic stroke. Opiates often cause infective endocarditis, resulting in ischemic stroke and hypereosinophilia accompanied by pyogenic arthritis, provoking hemorrhagic stroke. Genetic variants are linked to increased risk for stroke in cocaine abuse. The fact that case reports on cannabis-induced stroke usually refer to the young population is very alarming.

Verified
Journal Article
Open access
PDF file
MPMaria Pagoni
Maria Pagoni
CCClaudia Cava
Claudia Cava
DSDiamantis C. Sideris
Diamantis C. Sideris
Margaritis AvgerisMargaritis Avgeris
Margaritis Avgeris
VZVassilis Zoumpourlis
Vassilis Zoumpourlis
Nikolaos DrakoulisNikolaos Drakoulis
Nikolaos Drakoulis
The discovery of therapeutic miRNAs is one of the most exciting challenges for pharmaceutical companies. Since the first miRNA was discovered in 1993, our knowledge of miRNA biology has grown considerably. Many studies have demonstrated that miRNA expression is dysregulated in many diseases, making them appealing tools for novel therapeutic approaches. This review aims to discuss miRNA biogenesis and function, as well as highlight strategies for delivering miRNA agents, presenting viral, non-viral, and exosomic delivery as therapeutic approaches for different cancer types. We also consider the therapeutic role of microRNA-mediated drug repurposing in cancer therapy.

1 September 1995
Verified
Journal Article
Closed access
ICIngolf Cascorbi
Ingolf Cascorbi
Nikolaos DrakoulisNikolaos Drakoulis
Nikolaos Drakoulis
JBJ Brockmöller
J Brockmöller
AMA Maurer
A Maurer
KSK Sperling
K Sperling
IRI Roots
I Roots

1 January 2017 in Toxicology Reports
Verified
Journal Article
Open access
Anca Oana DoceaAnca Oana Docea
Anca Oana Docea
Loukia VassilopoulouLoukia Vassilopoulou
Loukia Vassilopoulou
DFDomniki Fragou
Domniki Fragou
AAAndreea Letitia Arsene
Andreea Letitia Arsene
CFConcettina Fenga
Concettina Fenga
Nikolaos DrakoulisNikolaos Drakoulis
Nikolaos Drakoulis
The association between genetic variations in the cytochrome P450 (CYP) family genes and pathological conditions related to long-term exposure to organochlorine compounds (OCs) deserves further elucidation. OCs are persistent organic pollutants with bioaccumulative and lipophilic characteristics. They can act as endocrine disruptors and perturb cellular mechanisms. Prolonged exposure to OCs has been associated with different pathological manifestations. CYP genes are responsible for transcribing enzymes essential in xenobiotic metabolism. Therefore, polymorphisms in these genetic sequences a. alter the metabolic pathways, b. induce false cellular responses, and c. may provoke pathological conditions. The main aim of this review is to define the interaction between parameters a, b and c at a mechanistic/molecular level, with references in clinical cases.

4 February 1992 in Biochemical Pharmacology
Verified
Journal Article
Closed access
JBJ. Brockmöller
J. Brockmöller
DGD. Gross
D. Gross
RKR. Kerb
R. Kerb
Nikolaos DrakoulisNikolaos Drakoulis
Nikolaos Drakoulis
IRI. Roots
I. Roots